Cover Image
Market Research Report

Global Ovarian Cancer Drugs Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 785663
Published Content info 117 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Ovarian Cancer Drugs Market 2019-2023
Published: February 1, 2019 Content info: 117 Pages
Description

About this market

Ovarian cancer is the second most common gynecologic cancer, and the incidence of the disease has been increasing. The incidence of ovarian cancer increases with age, mainly due to the cell DNA damage associated with age as a result of biological processes or due to the exposure to risk factors. In terms of the incidence rate, ovarian cancer is the eighth-most commonly occurring malignancy in women and the eighteenth-most common cancer overall. Thus, the increase in the incidence of ovarian cancer is expected to drive the growth of the global ovarian cancer drugs market during the forecast period. Technavio's analysts have predicted that the ovarian cancer drugs market will register a CAGR of over 22% by 2023.

Market Overview

Increasing awareness of ovarian cancer

The increasing awareness of ovarian cancer among physicians and patients is expected to drive the growth of the market during the forecast period. This has led to increased awareness among healthcare workers regarding the symptoms of ovarian cancer and the options to manage the disease.

High cost of treatment

The treatment of ovarian cancer is costly and imposes a high economic burden on the national healthcare system and on individuals. Hence, even though cost-effective oral chemotherapy drugs are available for the treatment of ovarian cancer often they are not offered to Medicare patients due to the above regulation and patients need to spend significant out-of-pocket costs. Hence, the cost of the treatment is a significant challenge in the market.

For the detailed list of factors that will drive and challenge the growth of the ovarian cancer drugs market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR30795

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1. Preface
  • 2.2. Preface
  • 2.3. Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Epithelial ovarian cancer - Market size and forecast 2018-2023
  • Germ cell ovarian cancer - Market size and forecast 2018-2023
  • Stromal cell ovarian cancer - Market size and forecast 2018-2023
  • Small cell ovarian cancer - Market size and forecast 2018-2023
  • Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Market trends

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Clovis Oncology
  • F. Hoffmann-La Roche
  • Spectrum Pharmaceuticals
  • TESARO

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global oncology therapeutics market
  • Exhibit 03: Segments of global oncology therapeutics market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Pipeline drugs in late-stage clinical trials
  • Exhibit 07: Market definition - Inclusions and exclusions checklist
  • Exhibit 08: Market size 2018
  • Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 11: Five forces analysis 2018
  • Exhibit 12: Five forces analysis 2023
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2018
  • Exhibit 19: Type - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by type
  • Exhibit 21: Epithelial ovarian cancer - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Epithelial ovarian cancer - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Germ cell ovarian cancer - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Germ cell ovarian cancer - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Stromal cell ovarian cancer - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 26: Stromal cell ovarian cancer - Year-over-year growth 2019-2023 (%)
  • Exhibit 27: Small cell ovarian cancer - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: Small cell ovarian cancer - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Market opportunity by type
  • Exhibit 30: Customer landscape
  • Exhibit 31: Market share by geography 2018-2023 (%)
  • Exhibit 32: Geographic comparison
  • Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: Decision framework
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendors covered
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: AstraZeneca - Vendor overview
  • Exhibit 51: AstraZeneca - Product segments
  • Exhibit 52: AstraZeneca - Organizational developments
  • Exhibit 53: AstraZeneca - Geographic focus
  • Exhibit 54: AstraZeneca - Key offerings
  • Exhibit 55: Clovis Oncology - Vendor overview
  • Exhibit 56: Clovis Oncology - Product segments
  • Exhibit 57: Clovis Oncology - Organizational developments
  • Exhibit 58: Clovis Oncology - Geographic focus
  • Exhibit 59: Clovis Oncology - Key offerings
  • Exhibit 60: F. Hoffmann-La Roche - Vendor overview
  • Exhibit 61: F. Hoffmann-La Roche - Business segments
  • Exhibit 62: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 63: F. Hoffmann-La Roche - Geographic focus
  • Exhibit 64: F. Hoffmann-La Roche - Segment focus
  • Exhibit 65: F. Hoffmann-La Roche - Key offerings
  • Exhibit 66: Spectrum Pharmaceuticals - Vendor overview
  • Exhibit 67: Spectrum Pharmaceuticals - Business segments
  • Exhibit 68: Spectrum Pharmaceuticals - Organizational developments
  • Exhibit 69: Spectrum Pharmaceuticals - Geographic focus
  • Exhibit 70: Spectrum Pharmaceuticals - Key offerings
  • Exhibit 71: TESARO - Vendor overview
  • Exhibit 72: TESARO - Business segments
  • Exhibit 73: TESARO - Organizational developments
  • Exhibit 74: TESARO - Geographic focus
  • Exhibit 75: TESARO - Key offerings
  • Exhibit 76: Validation techniques employed for market sizing
  • Exhibit 77: List of abbreviations
Back to Top